Obermatt
See Similar Stocks →

Centessa Pharmaceuticals

NSQ:CNTA · US1523091007
BiotechnologySmall

360

28
Medium confidence — indicative
Profit price78
Owner Earnings Yield1
Dividend Yield1
Price/Sales1
Price/Book3
Return on Capital26
Cash Return on Capital26
Return on Equity23
Profit margins28

Cash truth not applicable for financial companies.

Sales growth1
Profit growth19
Reinvestment38
Price momentum97
Debt load51
Refinancing54
Debt Payback1
Liquidity35
Analyst ratings5
Opinion Changes50
Price Target Upside21
Market mood47
Value Creation4/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Centessa Pharmaceuticals doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUK
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2020
Employees124
Websitecentessa.com
ISINUS1523091007
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
ImmunologyNeurologyRespiratorySleep TechnologyCentral Nervous SystemPsychiatryNeuroscienceOncology

Description

Centessa Pharmaceuticals plc operates as a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The company is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed t…

Analysis

Middle-of-the-road

Centessa Pharmaceuticals plc sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 4/20 on our value-creation score: not creating value. Analyst sentiment is cautious.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
18
2026

All-time high

54

Mar 2026

All-time low

18

Jun 2026

Average rank

36

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
1
—
—
—
Price/Earnings
90
—
—
—
Price/Book
3
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
47
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Centessa Pharmaceuticals with its peers
Compugen
NAQ:CGEN
19
CountryIsrael
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
OSE Immunotherapeutics
PAR:OSE
31
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Molecular Partners
SWX:MOLN
1
CountrySwitzerland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Tiziana Life Sciences
NAQ:TLSA
67
CountryUK
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
OKYO Pharma
NAQ:OKYO
40
CountryUK
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Immatics
NAQ:IMTX
31
CountryGermany
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →